Humanized pan-HER antibody compositions
US9527913B2 · kind B2 · utility
3Cited by
3References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 2013 |
| Grant date | Dec 27, 2016 |
| Priority date | — |
| Expiry date | May 2, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.